Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA-Mutated Ovarian Carcinoma”

74 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 74 results

Not applicableStudy completedNCT03471572
What this trial is testing

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India

Who this might be right for
Ovarian Cancer
AstraZeneca 240
Testing effectiveness (Phase 2)Active Not RecruitingNCT02571725
What this trial is testing

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
New Mexico Cancer Research Alliance 50
Testing effectiveness (Phase 2)WithdrawnNCT01661868
What this trial is testing

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Testing effectiveness (Phase 2)Study completedNCT01482715
What this trial is testing

Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+1 more
pharmaand GmbH 136
Not applicableLooking for participantsNCT07498829
What this trial is testing

Population Based Germline Testing for Early Detection and Prevention of Cancer

Who this might be right for
Breast Cancer RiskOvarian Cancer RiskCancer Gene Mutation
Queen Mary University of London 6,000
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Not applicableUnknownNCT05748353
What this trial is testing

Endocrine Disruptors and Life STILe in Breast Cancer Development

Who this might be right for
Breast CancerBRCA1 MutationBRCA2 Mutation+3 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 275
Testing effectiveness (Phase 2)Active Not RecruitingNCT06380660
What this trial is testing

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultBRCA1 MutationBRCA2 Mutation+3 more
Acerand Therapeutics (Shanghai) Limited 298
Not applicableNot Yet RecruitingNCT07764744
What this trial is testing

Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants

Who this might be right for
Ovarian NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation+2 more
Weill Medical College of Cornell University 70
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Early research (Phase 1)Study completedNCT01104259
What this trial is testing

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerHereditary Breast/Ovarian Cancer - BRCA1+6 more
University of Washington 50
Large-scale testing (Phase 3)Ended earlyNCT04729387
What this trial is testing

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Who this might be right for
Ovarian Cancer
Novartis Pharmaceuticals 358
Early research (Phase 1)UnknownNCT02225015
What this trial is testing

Cancer Prevention in Women With a BRCA Mutation

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationBreast Cancer+1 more
Women's College Hospital 300
Not applicableStudy completedNCT05775549
What this trial is testing

Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

Who this might be right for
Advanced Ovarian Cancer
AstraZeneca 24
Early research (Phase 1)Not Yet RecruitingNCT07088588
What this trial is testing

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid CancerMetastatic Solid TumorOvarian Cancer+3 more
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd 105
Post-approval studies (Phase 4)Study completedNCT02476968
What this trial is testing

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

Who this might be right for
BRCA or HRR+ Mutated Ovarian Cancer Patients
AstraZeneca 181
Large-scale testing (Phase 3)WithdrawnNCT02392676
What this trial is testing

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
AstraZeneca
Testing effectiveness (Phase 2)Ended earlyNCT04377087
What this trial is testing

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sarah E Taylor 3
Next Page